18 MARCH 2006

Ellex Medical Laser Ltd. (ASX:ELX), a world leading designer and manufacturer of laser systems for the ophthalmic industry, announced that it will introduce the Integre Duo, the world’s first solid-state red and green photocoagulator, today at the opening of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Francisco.

The Integre Duo is the world’s first red/green solid-state photocoagulator, bringing choice and versatility to ophthalmologists who treat challenging retinal conditions. The Integre Duo compliments Ellex’ comprehensive line of lasers for cataract, glaucoma and retina treatments.

Today, two thirds of the company’s revenue is derived from new products released in the past three years as a result of aggressive investment in R&D and distribution focused solely on the ophthalmic laser market.

Peter Falzon, Ellex’ CEO, commented “We have followed our customers asking to integrate the clinical utility and performance of the existing ion argon-krypton lasers and not compromising those benefits when choosing a solid-state laser today. The Integre Duo provides the benefits of both: simultaneous true red and green wavelength selection in a compact solid-state design.”

The Integre Duo has been approved for sale in Japan where the first customer units will be installed in April. Pending FDA clearance in the United States, the company expects the first customer units to arrive in the US market in July.

About Ellex

Ellex Medical Lasers Limited designs, manufactures and markets a complete line of lasers used by ophthalmologists to preserve vision and fight blindness. With more than 10,000 systems installed worldwide, Ellex has evolved from its starting point as an OEM supplier of ophthalmic lasers 15 years ago, to direct marketing of its own branded products through subsidiaries in the United States and Japan and through a network of distributors in more than 50 other countries. Ellex maintains a strong emphasis on intellectual property and research into new and better treatments to manage and cure the leading causes of blindness.